Healthy pipeline for cancer treatments: PhRMA

Share this article:
A report delivered by industry trade group PhRMA has found a record 750 potential cancer treatments in the US research pipeline, according to a statement.

The report was released in Baton Rouge, LA, where it had “particular relevance,” according to PhRMA senior vice president Ken Johnnson. “According to the Centers for Disease Control and Prevention, Louisiana has the highest death rate from cancer in the United States,” said Johnson.  

Billy Tauzin, PhRMA president, CEO and formerly a US Representative of Louisiana's 3rd congressional district, noted the strong commitment by America's pharmaceutical research companies. “The medicines now in the research pipeline will add to the substantial progress made in the last five years by biopharmaceutical companies in developing new and more effective cancer treatments,” he said.

Among cancer treatments in the pipeline, 113 are for lung cancer, 90 for breast cancer, 65 for colorectal cancer and 88 for prostate cancer, according to a statement. 

In 2008, it is estimated that 294,120 men and 271,530 women will die from cancer in the US, according to the American Cancer Society.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.